ClinicalTrials.gg
Not yet recruitingNCT07486479Updated Mar 20, 2026

Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

A Phase 3 interventional study of Mitoxantrone Hydrochloride Liposome and Venetoclax in Acute Myeloid Leukemia (AML), sponsored by The First Affiliated Hospital of Soochow University. Not yet recruiting at 21 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by The First Affiliated Hospital of Soochow University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 203 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 145 under way, 22 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Planned enrollment
28th of 203
204 · median 58
Started
2026
with 27 others
Phase 3
17 of 203
8 open now
Primary completion
2026-12
later than 41 of 144 live
Registered
181st of 203
by date
Lead sponsor
14 of 203
The First Affiliated Hospital of Soochow University

Among the 203 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 28th largest by planned enrollment, is one of 28 that started in 2026, is one of 17 in phase 3, reaches primary completion later than 41 of the 144 other live ones, and was the 181st registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 203 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of venetoclax combined with azacitidine and mitoxantrone hydrochloride liposome (MVA) versus idarubicin combined with cytarabine (IA) in the treatment of newly diagnosed AML.

Read the detailed description

For adult patients with newly diagnosed acute myeloid leukemia (AML) who are eligible for intensive chemotherapy, the standard intensive induction regimen remains anthracycline combined with cytarabine. However, the efficacy of traditional intensive chemotherapy is limited in high-risk AML and is associated with significant myelosuppression and infection risk, underscoring the need for novel therapeutic strategies. This study was therefore designed as a prospective, multicenter, randomized controlled trial. The study plans to enroll 204 adults with newly diagnosed AML. Participants will be randomized in a 2:1 ratio to receive induction therapy with either: 1) venetoclax, azacitidine, and mitoxantrone hydrochloride liposome (MVA), or 2) idarubicin and cytarabine (IA). The primary endpoint is the composite complete remission (CRc) rate following one cycle of induction therapy.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • Acute myeloid leukemia
  • mitoxantrone hydrochloride liposome
  • Venetoclax
  • Azacitidine
  • Idarubicin
  • Cytarabine
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. The patient fully understands the study, voluntarily participates, and has signed the form (ICF).

    2. Aged 18 to 65 years, any gender. 3. Newly diagnosed with AML according to the 2022 WHO classification. 4. Eligible for intensive chemotherapy as determined by the investigator. 5. (ECOG) performance status of 0 to 2. 6. ≥ 3 months. 7. Adequate liver and renal function: (ALT) and aspartate aminotransferase (AST) ≤ 3 × (ULN) (≤ 5 × ULN for patients with hepatic involvement); total ≤ 1.5 × ULN (≤ 3 × ULN for patients with hepatic involvement); serum creatinine ≤ 1.5 × ULN.

Exclusion criteria

Exclusion Criteria:

  • Patients who meet any of the following criteria will be excluded from the study:

    1. Any of the following conditions:

      1. Acute promyelocytic leukemia (APL);
      2. Central nervous system leukemia (CNSL);
      3. AML secondary to chemotherapy/radiotherapy for other or antecedent hematological disorders (e.g., MDS, MPN, CML);
    2. Prior treatment with hypomethylating agents (HMA) or venetoclax;
    3. Prior anti-AML therapy (except for leukocytosis management such as hydroxyurea or leukapheresis);
    4. History of other malignancies within the past 5 years (except for cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, or other malignancies that have been effectively controlled without treatment in the past five years);
    5. Inability to take oral medication or malabsorption syndrome;
    6. Cardiac function or disease meeting any of the following criteria:

      1. Long syndrome or QTc interval > 480 ms;
      2. Complete left bundle branch block, second- or third-degree atrioventricular block;
      3. Severe, uncontrolled arrhythmias requiring medication;
      4. (NYHA) Class ≥ II;
      5. (LVEF) \< 50%;
      6. History of myocardial infarction, unstable angina, severe unstable ventricular arrhythmia, or any other significant arrhythmia requiring treatment, pericardial disease within 6 months prior to enrollment, or evidence of acute ischemia or active conduction system abnormalities.
    7. Uncontrolled systemic illnesses (e.g., active infection, uncontrolled hypertension, diabetes);
    8. (HIV) infection (HIV antibody positive);
    9. Active or C infection (Hepatitis B: HBsAg or HBcAb positive, with HBV-DNA > 1×10³ copies/mL; : HCV-Ab positive, with HCV-RNA > 1×10³ copies/mL);
    10. Known history of immediate or delayed reaction to drugs of the same class or of the product;
    11. Significant neurological or psychiatric history;
    12. Pregnant or lactating women;
    13. Patients considered by the investigator to be unsuitable for participation in this study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    MVA

    Patients achieving complete remission (CR), CR with partial hematologic recovery (CRh), CR with incomplete hematologic recovery (CRi), or morphologic leukemia free state (MLFS) after Cycle 1 proceed to consolidation therapy. Patients achieving a partial response (PR) or demonstrating 50% blast reduction after Cycle 1 receive one additional cycle of re-induction with the same MVA regimen. Those who subsequently achieve CR, CRh, CRi, or MLFS after Cycle 2 proceed to consolidation. Patients with no response (NR) after Cycle 1, or those with NR or PR after Cycle 2, will discontinue study treatment.

    Drug: Mitoxantrone Hydrochloride Liposome · Drug: Venetoclax · Drug: Azacitidine

  • Active comparator
    IA

    Patients achieving CR, CRh, CRi, or MLFS after Cycle 1 proceed to consolidation therapy. Patients achieving a PR or demonstrating 50% blast reduction after Cycle 1 receive one additional cycle of re-induction with the same IA regimen. Those who subsequently achieve CR, CRh, CRi, or MLFS after Cycle 2 proceed to consolidation. Patients with NR after Cycle 1, or those with NR or PR after Cycle 2, will discontinue study treatment.

    Drug: Idarubicin · Drug: Cytarabine

Interventions

  • DrugLiposomal Mitoxantrone HydrochlorideStudies of Liposomal Mitoxantrone HydrochlorideLiposomal Mitoxantrone Hydrochloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mitoxantrone Hydrochloride Liposome: 24 mg/m², administered by intravenous drip (ivgtt) on day 1

  • Venetoclax: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-9, administered orally (po)

  • Azacitidine: 75 mg/m², administered subcutaneously (sc) on days 1-7

  • Idarubicin: 12 mg/m², administered by intravenous drip (ivgtt) on days 1-3

  • Cytarabine: 100 mg/m², administered by intravenous drip (ivgtt) on days 1-7

06

What researchers measure

Primary outcomes

  1. Composite Complete Remission(CRc) rate after one cycle of induction therapy

    Complete remission plus complete remission with partial hematologic recovery plus complete remission with incomplete hematologic recovery (CR+CRh+CRi). Response is assessed according to the the European LeukemiaNet (ELN) 2022 criteria.

    Time frame: At the end of the first treatment cycle (Day 28 ± 7), each cycle is 28 days).

Secondary outcomes

  1. Measurable residual disease (MRD) negativity rate (by flow cytometry and molecular testing) among patients who achieved CRc after induction therapy

    Percentage of participants who achieve a CRc MRD- as defined by investigators based on ELN 2022 criteria.

    Time frame: At the end of each cycle (Day 28 ± 7), each cycle is 28 days, up to 2 cycles.

  2. Overall response rate(ORR) to induction therapy

    CRc+morphologic leukemia-free state (MLFS)+partial remission (PR). Response is assessed according to the the European LeukemiaNet (ELN) 2022 criteria.

    Time frame: At the end of each cycle (Day 28 ± 7), each cycle is 28 days, up to 2 cycles

  3. Time to CRc

    Defined as the time from day 1 of the treatment until the patient achieves CRc. Response is assessed according to the the European LeukemiaNet (ELN) 2022 criteria.

    Time frame: Within 100 days from day 1 of treatment.

  4. 1-year relapsed-free survival (RFS) rate

    Defined only for patients achieving CRc. Measured from the date of achievement of remission until the date of hematologic relapse or death from any cause.

    Time frame: up to 1 years after the date of the last enrolled participants

  5. 1-year leukemia-free survival (LFS) rate

    Defined only for patients achieving CRc. Measured from day 1 of treatment to the date of first documented leukemia relapse or death from any cause.

    Time frame: up to 1 years after the date of the last enrolled participants

  6. 1-year overall survival (OS) rate

    Defined for all patients in the study. Measured from day 1 of treatment to the date of death from any cause.

    Time frame: up to 1 years after the date of the last enrolled participants

  7. Incidence of treatment-emergent adverse events, transfusion volume and time to hematologic recovery

    Safety assessments included adverse events (graded by NCI CTCAE v5.0), the number of units of red blood cells and platelets transfused, time to neutrophil recovery to ≥0.5x10⁹/L, and time to platelet recovery to ≥20x10⁹/L.

    Time frame: From day 1 of treatment to 28(±7) days after the last dose

  8. Change in Health-Related Quality of Life Assessed by EQ-5D-5L

    EuroQol 5-Dimension 5-Level (EQ-5D-5L) is a standardized instrument for measuring generic health-related quality of life. It comprises a descriptive system (generating a health utility score for cost-utility analysis) and a Visual Analogue Scale (EQ VAS) recording the participant's self-rated health. Recommended assessment time points: Baseline, end of Cycle 1 induction therapy (Day 28 ± 7, assessable after completion of bone marrow aspiration), end of Cycle 2 induction therapy (Day 28 ± 7), end of consolidation therapy, first follow-up after transplantation, and follow-up after first relapse.

    Time frame: up to 1 years after the date of the last enrolled participants

  9. Change in Cancer-Specific Quality of Life Assessed by EORTC QLQ-C30

    The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is a cancer-specific instrument. It includes a Global Health Status/Quality of Life scale, five functional scales (physical, role, emotional, cognitive, social), and nine symptom scales/items (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). Recommended assessment time points: Baseline, end of Cycle 1 induction therapy (Day 28 ± 7, assessable after completion of bone marrow aspiration), end of Cycle 2 induction therapy (Day 28 ± 7), end of consolidation therapy, first follow-up after transplantation, and follow-up after first relapse.

    Time frame: up to 1 years after the date of the last enrolled participants

  10. Total Direct Medical Costs

    Total direct medical costs (including costs of study drugs, concomitant medications, hospitalization, outpatient visits, laboratory tests, and management of adverse events) incurred over the study period. Costs will be estimated based on patient-level resource utilization data collected during the trial and, if applicable, extrapolated using a long-term simulation model. Unit of Measure: Currency (CNY)

    Time frame: up to 1 year after the date of the last enrolled participant

  11. Quality-Adjusted Life Years (QALYs)

    Quality-adjusted life years gained, calculated by integrating survival data with health utility weights derived from the EQ-5D-5L questionnaire administered at specified time points during the trial. A long-term simulation model may be used to extrapolate QALYs beyond the observation period. Unit of Measure: Years

    Time frame: up to 1 year after the date of the last enrolled participant

07

Study locations

21 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's planned 9 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Mar 20, 2026
StartEst.
Mar 10, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07486479
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Mar 10, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 20, 2026

Study contacts

Xiaowen Tang
Contact
tangxiaowen@suda.edu.cn
0512-67780103
Depei Wu
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Azacitidine

Start the discussion